DL Wagner Genome Engineering Labs
@dlwagnerlabs.bsky.social
International research group (Berlin & Houston) led by @dlwagner.bsky.social
CAR-T cells | Non-viral genome engineering | CRISPR | Precision editing | Large knock-ins | Integrases |
CAR-T cells | Non-viral genome engineering | CRISPR | Precision editing | Large knock-ins | Integrases |
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
October 5, 2025 at 8:51 PM
Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura
Lab History pt. 6 (2025)
For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ?
www.cell.com/molecular-th...
For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ?
www.cell.com/molecular-th...
September 18, 2025 at 12:49 AM
Lab History pt. 6 (2025)
For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ?
www.cell.com/molecular-th...
For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ?
www.cell.com/molecular-th...
Lab History pt. 5 (2025)
What is the best Knock-in strategy to make CAR-Tregs??
our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...
What is the best Knock-in strategy to make CAR-Tregs??
our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...
September 18, 2025 at 12:38 AM
Lab History pt. 5 (2025)
What is the best Knock-in strategy to make CAR-Tregs??
our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...
What is the best Knock-in strategy to make CAR-Tregs??
our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...
Lab History pt. 4 (2024)
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
September 18, 2025 at 12:29 AM
Lab History pt. 4 (2024)
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
What could be BETTER THAN TRAC KNOCK-IN ??
CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...
Lab History pt. 3 (2023)
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
September 18, 2025 at 12:23 AM
Lab History pt. 3 (2023)
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!
HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.
Published in Blood Advances 🔗 ashpublications.org/bloodadvance...
Lab History pt. 2 (2023)
Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO.
=> Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%.
Published in Genome Biology. 🔗 link.springer.com/article/10.1...
Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO.
=> Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%.
Published in Genome Biology. 🔗 link.springer.com/article/10.1...
September 18, 2025 at 12:13 AM
Lab History pt. 2 (2023)
Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO.
=> Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%.
Published in Genome Biology. 🔗 link.springer.com/article/10.1...
Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO.
=> Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%.
Published in Genome Biology. 🔗 link.springer.com/article/10.1...
Lab History pt. 1
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018
September 17, 2025 at 11:51 PM
Lab History pt. 1
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018
2022 – 🚨 Our first paper is out! 🚨
virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.
➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation
🧬 A key step toward scalable, non-viral CAR-T cell therapies.
DOI: 10.1016/j.omtm.2022.03.018